Oncolytics Biotech Inc. announced positive updated clinical data from its Phase 1/2 GOBLET study for its investigational immunotherapy, pelareorep. The results from Cohort 4, evaluating pelareorep in combination with atezolizumab for second-line squamous cell anal cancer, showed a strong and durable response, supporting further development and a potential registrational pathway.
Key Details
- Primary Finding: The study demonstrated an approximate 15-month median duration of response, which favorably exceeds the 9.5-month duration for an approved second-line checkpoint inhibitor monotherapy.
- Survival Data: 100% of patients who responded to the treatment survived for longer than one year, with some surviving over 24 months.
- Strategic Outlook: Supported by an FDA Fast Track Designation, the company plans to pursue a registrational path for this indication and expand pelareorep's use into other HPV-driven cancers, including head and neck cancer.